Download our whitepaper,
"Inflammatory Bowel Disease (IBD): Treatment Drugs Approved, Failed and Lessons Learned"
What's Inside:
- Key FDA-Approved Pivotal Endpoints for IBD Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for IBD.
- Comprehensive Analysis of FDA-Approved IBD Drugs.
- How Diagnostic Criteria for IBD Have Evolved and Impact Research.
- Overcoming Common Pitfalls in IBD Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a prevalent and significantly impactful gastrointestinal condition that profoundly influences a person's digestive health and overall well-being.
It is distinguished by persistent inflammation and irritation of the digestive tract, leading to symptoms such as abdominal pain, diarrhea, and weight loss.
IBD can also have broader implications for a person's quality of life, affecting their daily activities, social interactions, and emotional well-being. Additionally, the chronic nature of IBD can contribute to long-term physical and emotional challenges, making it a complex and challenging condition to manage.
iNGENū’s team of researchers and clinicians is dedicated to advancing Inflammatory Bowel Disease research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by Inflammatory Bowel Disease.
10 Million
people affected worldwide
IBD is more common in developed countries, particularly in North America and Europe
The incidence of IBD has been increasing globally.
It often develops in people in their late teens and early twenties, but it can occur at any age
Our clinical team has over
120
years of combined experience